Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Journal of Clinical Medicine|May 22, 2019
Factors for the Early Revision of Misdiagnosed Tuberculosis to Lung Cancer: A Multicenter Study in A Tuberculosis-Prevalent AreaChin-Chung Shu, Shih-Chieh Chang, Yi-Chun Lai, et al.
Current Oncology (Toronto, Ont.)|March 26, 2025
Unraveling Survival Determinants in Patients with Advanced Non-Small-Cell Lung Cancer with EGFR Exon 20 InsertionsKung-Yang Wang, Shih-Chieh Chang, Yu-Feng Wei, et al.
Journal of the Chinese Medical Association : JCMA|March 19, 2013
Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinomaKo-Fan Wang, Cheng-Yu Chang, Shih-Chieh Chang, et al.
Drug Design, Development and Therapy|January 26, 2023
The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19Shih-Lung Cheng, Ping-Huai Wang, Cheng-Yu Chang, et al.
BMC Pulmonary Medicine|April 24, 2014
Comparative chest computed tomography findings of non-tuberculous mycobacterial lung diseases and pulmonary tuberculosis in patients with acid fast bacilli smear-positive sputumMei-Kang Yuan, Cheng-Yu Chang, Ping-Huang Tsai, et al.
International Journal of Medical Informatics|May 14, 2024
Pain prediction model based on machine learning and SHAP values for elders with dementia in TaiwanShwu-Feng Tsay, Cheng-Yu Chang, Sing Shueh Hung, et al.
BMC Cancer|November 16, 2021
Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patientsYou-Yi Chen, Shih-Chieh Chang, Cheng-Yu Chang, et al.
Molecular Diagnosis & Therapy|August 15, 2024
Profiling Cell-Free DNA from Malignant Pleural Effusion for Oncogenic Driver Mutations in Patients with Treatment-Naive Stage IV Adenocarcinoma: A Multicenter Prospective StudyShih-Chieh Chang, Yu-Feng Wei, Chung-Yu Chen, et al.
Frontiers in Oncology|July 6, 2023
Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatmentCheng-Yu Chang, Chung-Yu Chen, Shih-Chieh Chang, et al.
Translational Oncology|August 12, 2019
Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase InhibitorsShih-Chieh Chang, Yi-Chun Lai, Cheng-Yu Chang, et al.
Pageof 5